These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 6793403

  • 1. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
    Bergquist C, Nillius SJ, Wide L, Lindgren A.
    Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
    [Abstract] [Full Text] [Related]

  • 2. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
    Bergquist C, Nillius SJ, Wide L.
    Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
    [Abstract] [Full Text] [Related]

  • 3. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
    Hardt W, Schmidt-Gollwitzer K, Nevinny-Stickel J, Schmidt-Gollwitzer M.
    Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
    Kuhl H, Jung C, Taubert HD.
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
    [Abstract] [Full Text] [Related]

  • 6. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
    Baumann R, Kuhl H, Taubert HD, Sandow J.
    Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
    Nillius SJ, Bergquist C, Wide L.
    Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
    [Abstract] [Full Text] [Related]

  • 8. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
    Nillius SJ, Bergquist C, Wide L.
    Int J Fertil; 1980 Jun; 25(3):239-46. PubMed ID: 6108935
    [Abstract] [Full Text] [Related]

  • 9. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
    Lemay A, Jean C, Faure N.
    Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
    [Abstract] [Full Text] [Related]

  • 10. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B, Zeng T, Wu S, Sun H, Xiao N.
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [Abstract] [Full Text] [Related]

  • 11. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR, Gopalkrishnan K, Chwalisz K, Schillinger E, Puri CP.
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [Abstract] [Full Text] [Related]

  • 12. Endometrial morphology after 6 months of continuous treatment with a new gonadotropin-releasing hormone superagonist for contraception.
    Gudmundsson JA, Lundkvist O, Bergquist C, Lindgren A, Nillius SJ.
    Fertil Steril; 1987 Jul; 48(1):52-6. PubMed ID: 2954864
    [Abstract] [Full Text] [Related]

  • 13. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A, Faure N.
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [Abstract] [Full Text] [Related]

  • 14. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Lemay A, Quesnel G.
    Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
    [Abstract] [Full Text] [Related]

  • 15. Ovulation inhibition with nafarelin acetate nasal administration for six months.
    Brenner PF, Shoupe D, Mishell DR.
    Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist.
    Bergquist C, Nillius SJ, Wide L.
    Contraception; 1979 May; 19(5):497-506. PubMed ID: 380892
    [Abstract] [Full Text] [Related]

  • 17. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB, Massai MR, Salvatierra AM, Fuentealba B, Croxatto HD, Lähteenmäki P.
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.
    Gudmundsson JA, Nillius SJ, Bergquist C.
    Contraception; 1984 Aug; 30(2):107-14. PubMed ID: 6238805
    [Abstract] [Full Text] [Related]

  • 19. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.
    Gemzell-Danielsson K, Swahn ML, Svalander P, Bygdeman M.
    Hum Reprod; 1993 Jun; 8(6):870-3. PubMed ID: 8345076
    [Abstract] [Full Text] [Related]

  • 20. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
    Johannisson E, Brosens I, Cornillie F, Elder M, White J, Sheppard B, Hourihan H, d'Arcangues C, Belsey EM.
    Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.